Rafferty Asset Management
DNTH icon

Rafferty Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Rafferty Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.52M Buy
36,121
+4,900
+16% +$428K 0.01% 485
2026
Q1 		$2.62M Sell
31,221
-26,654
-46% -$1.54M 0.01% 555
2025
Q4 		$2.39M Buy
57,875
+40,544
+234% +$1.57M 0.01% 610
2025
Q3 		$682K Sell
17,331
-11,191
-39% -$286K ﹤0.01% 856
2025
Q2 		$531K Buy
28,522
+4,650
+19% +$87.2K ﹤0.01% 874
2025
Q1 		$433K Sell
23,872
-4,587
-16% -$101K ﹤0.01% 896
2024
Q4 		$620K Sell
28,459
-2,188
-7% -$56.3K ﹤0.01% 873
2024
Q3 		$839K Buy
+30,647
New +$854K ﹤0.01% 833

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Rafferty Asset Management's DNTH Position: Q2 2026 in Review

Rafferty Asset Management increased its Dianthus Therapeutics (DNTH) stake by 16% in Q2 2026, buying an estimated $428K and bringing the position to 36,121 shares worth $3.52M. The position accounts for 0.01% of the portfolio, ranked #485.

Rafferty Asset Management first reported a position in DNTH in Q3 2024 and has held it in 8 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Rafferty Asset Management held 36,121 shares of Dianthus Therapeutics worth $3.52M as of Q2 2026.
  • Rafferty Asset Management bought 4,900 Dianthus Therapeutics shares in Q2 2026, an estimated $428K.
  • Dianthus Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #485 holding.
  • Rafferty Asset Management first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.